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pathway. C functions include lysis of microbes, opsonization, attraction and activation of leucocytes and enhancement of the
inflammatory response.
In the present study the aim was to look into whether Plasmodium falciparum (Pf) interferes with the complement at the level of
C3 by accelerating C3b inactivation and thus inhibit the amplification of the C cascade. Considering the characteristics of Pf
infection it is obvious that the plasmodia must somehow avoid complement attack.
Flow cytometric analysis (FACS), enzyme-linked immunosorbent assays (ELISA), immunoblotting assays and matrix assisted
laser desorption/ionization (MALDI) were used to determine if Pf evade C attack by acquisition of the host C inhibitors, factor H
(FH) and C4b binding protein (C4bp), from serum. FH is the major regulator of the alternative-pathway while C4bp is an inhibitor
of the classical-pathway. We also studied binding of complement components, especially C3, to Pf cells.
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a putative C3-binding merozoite-stage Pf protein was observed. Previously, it has been suggested that Plasmodium spp.
merozoites adsorb C3 fragments to their surface to gain entry into erythrocytes via CR1-receptor. No binding of C4bp was
detected.
Further studies are required to reveal the complement resistance mechanisms of Pf. Elucidation of Pf-C interactions will be of
great importance for our understanding of the principles of Plasmodium immunoevasion that affect directly the virulence of the
microbe. By identifying factors whereby Pf evades C, it is possible to understand better how the microbe causes disease and,
ultimately, how this could be prevented.
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Malaria lukeutuu maailmanlaajuisesti tärkeimpiin infektiotauteihin. Vuosittain siihen sairastuu 300-500 miljoonaa ihmistä, joista
menehtyy 1,5-2,5 miljoonaa. Valtaosa kuolonuhreista on alle viisivuotiaita afrikkalaisia lapsia. Malarian aiheuttaa Plasmodiidae-
heimon itiöeläimiin (Sporozoa) kuuluva Plasmodium –alkueläinloinen eli horkkaloisio. Ihmisellä kliinisen taudin voivat aiheuttaa
lajit P. falciparum (Pf), P. vivax, P. ovale sekä P. malariae. Falciparum-malaria on yleisin ja vaarallisin aiheuttamiensa
komplikaatioiden sekä kehittämänsä lääkeresistenssin johdosta. Malaria tarttuu ihmisestä toiseen Anopheles-suvun hyttysen
piston välityksellä.
Komplementti (K) on ryhmä veren proteiineja, joiden tehtävänä on tuhota ja poistaa kehoon joutuneita mikrobeja ja vieraita
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konvertaasientsyymi ja C3b käynnistää loppupään K aktivaation, jonka seurauksena muodostuu mikrobien lyysin aiheuttama
MAC-kompleksi. Huomattava osa komplementin säätelytapahtumista osallistuu C3:n aktivaatioon, jota estävät spesiset plasman
liukoiset säätelijämolekyylit mm. C4bp sekä tekijä H.
Tutkimuksen tavoitteena oli selvittää Pf-K-interaktioita. Erityisesti tutkimme estääkö Pf K:n toimintaa lisäämällä C3b:n
inaktivaatiota. Tutkimme C3:n sitoutumista Pf –infektoituihin punasoluihin ja merotsoiitteihin. Tutkimme myös estääkö Pf K:n
toimintaa sitomalla C4bp:tä ja FH:ta. Tutkimuksessa käytettiin virtaussytometriaa (FACS), entsyymi-immunologisia määrityksiä
(ELISA) sekä immunoblottausta.
Virtaussytometrialla todettiin lisääntynyt FH sitoutuminen Pf-infektoituneisiin punasoluihin. Lisäksi todettiin mahdollinen C3
sitoutuminen Pf-soluihin. Jatkotutkimukset ovat kuitenkin tarpeen Pf-K-interaktioiden selvittämiseksi ja varsinaisesta
komplementtisuojasta vastaavien molekyylien löytämiseksi.
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AP alternative pathway of complement
ASP apical sushi protein
BSA bovine serum albumin
C complement
C1-INH C1-inhibitor
C4bp C4b-binding protein
CD cluster of differentiation
CP classical pathway of complement
CR1 complement receptor 1
CSP circumsporozoite protein
DAF decay -acclerating factor
ECL electrochemical luminescence
ELISA enzyme-linked immunosorbent assay
FITC fluorescein isothiocyanate
FH factor H
GPI glycosyl-phosphatidylinositol
HAE hereditary angioedema
HCl hydrochloric acid
HIV human immunodeficiency virus
IL interleukin
IgG immunoglobulin G
kDa kilodalton
MAC membrane attack complex
MALDI matrix assisted laser desorption/ionization
MASP MBL-associated serine protease
MBL mannose binding lectin
MCP membrane cofactor protein
MFI mean fluorescence intensity
NHS normal human serum
PBS phosphate buffered saline
Pf Plasmodium falciparum
PfEMP1 Plasmodium falciparum erythrocyte membrane protein 1
PfHRP-2 Plasmodium falciparum histidine-rich protein-2
pLDH plasmodium specific lactate dehydrogenase
PMMSA the precursor of the major merozoite surface antigen
PNH paroxysmal nocturnal hemoglobinuria
PCR polymerase chain reaction
RBC red blood cell
RESA ring-infected erythrocyte surface antigen
RCA regulator of complement activation
RT room temperature
SCR short consensus repeat
SDS-PAGE sodium-dodecyl sulphate polyacrylamide gel electrophoresis
SLE systemic lupus erythematosus
SPf66 synthetic tripeptide vaccine
TEP1 thioester-containing protein 1
TNF-? tumor necrosis factor ?
TRAP thrombospondin related anonymous protein
TSR thrombospondin-like repeat
VBS veronal buffered saline
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71  INTRODUCTION
1.1 MALARIA
1.1.1 EPIDEMIOLOGY
Figure 1.1  Distribution of human malaria in the world (Whittle 1994).
Malaria continues to be a major global health problem, with more than 2400
million people exposed to malaria risk in over 100 countries (WHO, Management
of Severe Malaria 2000). Malaria is widely distributed throughout the tropics
(Whittle 1994). There are estimated 300 million to 500 million new Plasmodium
infections and 1.5 million to 2.7 million deaths each year. Transmission cannot
occur at mean temperatures outside the range from 16?C to 33?C or above 2000
m altitude, because development in the mosquito cannot take place (Rogers
2003). In areas where malaria is endemic, such as in sub-Saharan Africa, the
most severe mortality occurs in early childhood and the majority of deaths are
due to severe anemia. All forms of malaria can be transmitted transplacentally or
by blood transfusion.
81.1.2 ETIOLOGY
The agent of malaria is an Apicomplexan protozoon plasmodium. Plasmodia are
characterized by the presence of an apical complex consisting of polar rings,
conoid micronemes, rhoptries and subpellicular microtubules (Rogers 2003). The
genus Plasmodium includes at least 172 named species of intraerythrocytic
parasites infecting a wide range of mammals, birds, reptiles and amphibians
(Levine, 1988). Four species, Plasmodium falciparum (Pf), P. vivax, P. ovale and
P. malariae, commonly infect humans. Rarely, other species normally infecting
nonhuman animals may infect humans (Rogers 2003).
Pf causes the most serious form of malaria and is the most common species in
the tropics (WHO, Management of Severe Malaria 2000). Plasmodium falciparum
predominates in Africa, Haiti, Dominican Republic, French Guinea, Surinam,
parts of Asia and Papua New Guinea. P. vivax predominates in Latin America,
Turkey, the Indian subcontinent and China. P. malariae is widely distributed but
much less common than either of the former species. P. ovale occurs mainly in
Africa (Whittle 1994).
91.1.3 LIFE CYCLE
Malaria sporozoites are the infective developmental stage for man. Sporozoites
develop within the female Anopheles midgut and migrate anteriorly to its salivary
glands prior to inoculation into the mammalian host during blood meal (Perlmann
2002). Once inoculated into the host, the sporozoites rapidly (usually within 1
hour) enter liver hepatocytes (Brooks 2001) where they develop into exo-
erythrocytic forms. The intra-hepatocytic parasites multiply and numerous
asexual progeny, the merozoites, are released from hepatocytes into circulation
where they bind and invade human erythrocytes. Depending upon malaria
species, intra-erythrocytic asexual parasites multiply synchronously at 48-hour
intervals (P. falciparum, P. vivax and P. ovale) or every 72 hours (P. malariae)
(Brooks 2001) to form mature trophozoites and schizonts. The parasitized red
cells rupture releasing merozoites to launch another round of erythrocyte
invasion and proliferation (the erythrocytic cycle) (Perlmann 2002).
Figure 1.2  Schematic drawing of the life cycle of malaria parasites  (Perlmann 2002)
10
Pf invades red cells of all ages, including the erythropoietic stem cells in bone
marrow, so parasitemia may be very high, whereas P. vivax, P. ovale and P.
malariae favor either young or old red cells but not both and thus parasitemias
are relatively low-grade. Pf also causes changes in erythrocyte size, shape, and
deformability. Insertion of parasite antigens to the surface of the erythrocyte
membrane is associated with the formation of protuberances known as knobs,
which makes the cells sticky so that red cells infected with schizonts adhere to
capillary endothelia in the spleen, brain and other organs with resulting
obstruction, thrombosis and local ischemia (Whittle 1994). Pf infections are
therefore far more serious that those caused by other species with a much higher
rate of severe and frequently fatal complications (Brooks et al. 2001).
The incubation period includes the exoerythrocytic cycles (usually two) and at
least one or two erythrocytic cycles. For P. falciparum and P. vivax the latter
period is usually 10-15 days, but may be weeks or months. The incubation period
for P. malariae averages about 28 days (Brooks et al. 2001). In P. vivax and P.
ovale infection persisting nongrowing resting forms, hypnozoites, may develop
causing relapses for up to 5 years (Brooks et al. 2001). Plasmodium falciparum,
on the contrary, does not have a secondary life cycle, and relapses are thus
unknown after the parasite has been eradicated with treatment (Whittle 1994).
During a human Pf infection, parasites multiply asexually within the red blood cell
every 2 days. Some forms, however, enter a nonpathological sexual phase by
developing over 10-14 days into male and female gametocytes (Gerloff, D. L.
2005). The sexual cycle therefore begins in the vertebrate host, but for its
continuation into the sporogonic phase, sexual stage gametocyte parasites must
be ingested by Anopheles mosquitoes (Brooks et al. 2001). The male
gametocytes, microgametocytes, each produce 4-8 flagellae and fertilize the
female gametocytes, macrogametocytes, to form a zygote (WHO, Basic Malaria
Microscopy). When ingested by a blood-feeding mosquito, the gametocytes
emerge from the red cells as extracellular male and female gametes in the
11
mosquito midgut, where they fertilize to form a zygote. They invade mosquito
epithelial cells and develop into cysts that rupture and release sporozoites, which
enter the salivary glands. After 7-14 days the anopheline mosquito is able to
transit malaria (WHO, Basic Malaria Microscopy).
1.1.4 PATHOGENICITY AND DISEASE
The characteristic clinical manifestation of malaria in humans is the febrile
paroxysm, which begins with chills and rigors. The typical periodicity of these
paroxysms is 48 h with Pf infections (Rogers 2003). The patient commonly
complains of nausea, headache, myalgia and malaise and occasionally of
abdominal pain, vomiting and diarrhea (WHO, Management of Severe Malaria
2000). Also splenomegaly, hepatomegaly and normocytic anemia are common.
Infection with Pf may be complicated by severe malaria, which includes cerebral
malaria, generalized convulsions, severe normocytic anemia (hematocrit < 20%),
hyperparasitemia (>5%), hypoglycemia, metabolic acidosis, acute renal failure,
jaundice, disseminated intravascular coagulation, shock or development of adult
respiratory distress syndrome (Rogers 2003, WHO Management of Severe
Malaria 2000).
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1.1.5 DIAGNOSTICS
The diagnosis of malaria is usually based on
symptoms and identification of plasmodial
trophozoite stages in Giemsa-stained thick and
thin blood smears (WHO Basic Malaria
Microscopy, 1991). Each parasite has a
distinctive morphology and characteristic antigens
at each stage of its life cycle (Whittle 1994).
There are a number of alternative methods
including microhematocrit centrifugation and
staining with acridine orange (Rickman 1989),
PCR (Barker 1992) and antigen (Plasmodium
falciparum histidine-rich protein-2, PfHRP-2 and
Plasmodium-specific lactate dehydrogenase
pLDH) detection (Craig 1997, Shiff 1993, Beadle
et. al. 1994).
1.1.6 TREATMENT AND PREVENTION
The means to control malaria include elimination of mosquito breeding places
(spraying and drainage), personal protection against mosquitoes (screens, use of
pyrethrin-impregnated bednets, protective clothing, repellents), suppressive
drugs for exposed persons and adequate treatment of cases and carriers
(Brooks 2001).
Attemps in the 1960s to eradicate the disease by spraying the anopheline
mosquito vector failed as insecticide resistance developed (Whittle 1994). A
Figure 1.3 P. falciparum morphology in Giemsa-
stained thick blood smears. There are multiple
trophozoites (rings) and crescent-shaped
gametocytes. (Rogers 2003)
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further complication has been the rapid and widespread development of drug
resistance in many areas of the world (Whittle, 1994).
Pf resistance to chloroquine, which is the drug of choice for susceptible forms of
malaria, is present in most areas of endemicity. Also resistance to mefloquine
and sulfadoxine-pyramethamine is expanding rapidly. The combination of
quinidine and doxycyclin remains effective against most strains of Pf.
Artemesinin has shown promising results (Rogers 2003). Chemoprophylaxis is
usually started 1 week before travel and continued 4-6 weeks following return
from endemic areas.
No vaccine against malaria is available at the moment. A successful vaccine
against malaria is likely to consist of a variety of antigens derived from different
stages of the life cycle raising both humoral and cellular immunity. The gene
responsible for the sporozoite coating circumsporozoite (CSP) antigen has been
identified and cloned. An antisporozoite vaccine has been developed but its initial
testing in humans has not been successful (Brooks et al. 2001). A continuous
cultivation of erythrocytic phase plasmodia undergoing schizogony has been
achieved and is of critical importance in vaccine development (Brooks et al.
2001). A synthetic tripeptide vaccine, SPf66, has been tested in several trials and
found to be relatively ineffective (protection rate < 50%). Vaccine candidate-
antigens include CSP, the precursor of the major merozoite surface antigen
PMMSA and ring-infected erythtrocyte surface antigen RESA/Pf155 (Perlmann
2002)
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1.2  COMPLEMENT SYSTEM
1.2.1  COMPLEMENT COMPONENTS
The complement system (C) is a part of the innate immune system and consists
of more than 30 soluble or membrane-bound proteins (Prodinger et al. 1999).
Complement proteins circulating in blood plasma together make up to 10% of
globulin fraction of serum (Tizard 2000). The proteins for the complement system
are either numerically labeled with the prefix C (for example C1, C2, C3) or
designated by letters of the alphabet (B, D etc.) The molecular weights of the
complement components vary between 24 kDa for factor D to 460 kDa for C1q.
Serum concentrations vary from 20 ?g/ml for C2 to 1300 ?g/ml for C3, which is
the most important component of C. C3 is a heterodimer that consists of ? and ?
chains linked by a disulfide bond. The majority of C components are synthesized
in the liver (for example C3, C6, C8 and B) and in macrophages (such as C2,C3,
C4, C5, B, D, P, I). Neutrophils store large quantities of C6 and C7 (Tizard 2000).
Notably, C1q and C7 are not produced by the liver.
1.2.2. COMPLEMENT ACTIVATION PATHWAYS
Complement activation relies initially on a cascade of proteolytic steps performed
by serine protease domains in the components involved (Prodinger et al. 1999).
Most of these proteins are inactive until they are cleaved by a protease which, in
turn, converts them into an active protease. Many components of the system
serve as a substrate for a prior component and as an enzyme for a subsequent
component producing thus an expanding activation cascade (Tizard 2000). The
complement system can be activated through several different pathways. Three
different pathways of activation have been recognized, triggered by either target-
bound antibody (the classical pathway, CP), by recognition of foreign surface
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structures by C itself (the alternative pathway, AP) or by polysaccharide
structures of microbes (the lectin pathway). All three merge into activation of C3
and, consequently, C5. In the common terminal pathway, further C components
are activated in a nonproteolytic manner and assembled into the membrane
attack complex (MAC), which can directly bring about lysis of microbes
(Prodinger et al. 1999).
1.2.2.1  CLASSICAL COMPLEMENT PATHWAY
Figure 1.4 The basic features of the classical complement pathway (Tizard 2000)
The CP is triggered by the binding of antibody to its antigen. The first component
in the CP, C1, consists of three separate proteins (C1q, C1r, C1s) bound
together by calcium bonds.  C1 can be activated by a single, antigen-bound
molecule of IgM or paired, antigen-bound molecules of IgG (Tizard, 2000). Other
activators of CP include C-reactive protein (CRP), nucleic acids and damaged
cell membranes (Claus 1976, Jiang 1992, Nauta 2002). Binding of C1q activates
in turn C1r and C1s. Activated C1s (serine protease) acts on C4, breaking off a
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small C4a fragment, and leaving a large fragment called C4b (Tizard 2000).
Subsequently, C4b attaches covalently to amino acid or hydroxyl groups on
nearby surfaces by an exposed thioester site (Dodds 1996, Law 1987). C2 binds
to membrane-bound C4b and becomes cleaved forming the complex C4b2b.
This complex constitutes the CP C3 convertase as it catalyzes the cleavage of
C3 to C3a and C3b (Cooper 1975). The activation of C3b is the major step since
each C4b2b complex can activate as many as 200 C3 molecules (Tizard 2000).
As a result large numbers of C3b molecules expose the buried internal thioester
bond and are covalently attached to nearby surfaces either to OH- or NH2 -
groups. The polypeptide C3a acts as a potent anaphylatoxin (Prodinger et al.
1999).
1.2.2.2   ALTERNATIVE COMPLEMENT PATHWAY
Figure 1.5 The alternative complement pathway. Surface-bound C3b may either be initiated, as normally happens on host
cells, or activated by the presence of an activating surface (Tizard  2000).
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The AP was probably present about 500 millions of years ago and is found in the
most primitive vertebrates like lamprey or hagfish (Farries et al. 1991). C3 is
constantly spontaneously converted to C3b. Under normal circumstances host
cell surface containing sialic acid binds a protein called factor H (FH) and C3b is
inactivated by the protease factor I. In contrast to mammalian cells in which the
surface glycoproteins are heavily sialylated, microbial walls often lack sialic acid.
Thus C3b is not inactivated and it attaches to factor B to form C3bBb by factor D.
C3bBb is a potent alternative pathway C3-convertase. Properdin (factor P)
extends its half-life (Tizard 2000).
1.2.2.3 LECTIN PATHWAY
When macrophages ingest foreign material they are stimulated to secrete IL-1,
IL-6 and TNF-?. These cytokines act on hepatocytes stimulating secretion of
acute phase proteins including mannose-binding lectin (MBL). MBL is a large
molecule resembling C1q in structure. It binds to polysaccharides rich in
mannose and N-acetylglucosamine residues, which are present on some
bacterial and fungal walls (Jarva 2004). MBL is associated with two serine
proteases, MBL-associated serine protease –1 and –2 (MASP-1 and –2) (Sato
1994, Thiel 1997), which activate the CP by cleaving C2 and C4 (Tizard 2000).
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1.2.2.4 TERMINAL COMPLEMENT PATHWAY AND MEMBRANE ATTACK
COMPLEX
Figure 1.6 The terminal complement pathway leads eventually to the formation of a membrane attack complex (Tizard
2000).
The terminal pathway is initiated by the binding of C5 to C3b on microbial surface
and C5a and C5b fragments are produced. C5a is a potent anaphylatoxin and
chemotactic for neutrophils. C5b serves as the anchor for forming of the
membrane attack complex (MAC), which incorporates a single molecule of C5b,
C6, C7 and C8 and 12-18 polymerized C9 molecules that form a transmembrane
channel (Tschopp 1982). If sufficient numbers of MACs are formed on a target,
osmotic lysis occurs.
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1.2.3 EFFECTOR FUNCTIONS OF COMPLEMENT
Complement acts in several ways in mobilizing defense mechanisms. It is
involved in the initiation of adaptive immune responses because antibody-
independent, complement-mediated opsonization of microbes facilitates uptake
and presentation of antigens via complement receptors. Complement activation
results in cell lysis eliminating several pathogens (Prodinger et al. 1999).
Activation of C generates several chemotactic peptides and anaphylatoxins,
including C5a, C3a (Tizard 2000). Complement acts is the removal of large
immune complexes and solubilizes precipitated complexes (Jarva 2004).
Figure 1.7   The activation of the complement system by parasite, its evasion and effector functions (Hunter 2002).
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1.2.4  REGULATION OF COMPLEMENT ACTIVITY
Figure 1.8 The basic control mechanism of the complement system (Tizard 2000)
As a potentially self-damaging mechanism, C activation has to be avoided or at
least restricted on autologous cells (Prodinger et al. 1999). Substrate modulation
is important in preventing uncontrolled C activation i.e. proteins are secreted in
an inactive form and require a cleavage until they are activated.
Both soluble regulators and membrane-bound regulators keep C activation under
control. Soluble regulators include inhibitors C1-inhibitor (C1-INH), C4b- binding
protein (C4bp), FH and Factor H protein family, factor I and properdin, which is
the only known physiological positive regulator of C. To date, four membrane-
bound regulators of C have been identified in man. Three of these (membrane
cofactor protein MCP/CD46, decay accelerating factor, DAF/CD55 and
complement receptor 1 CR1/CD35) inhibit the C3 and C5 convertases and one
(protectin, CD59) inhibits the formation of MAC (Jarva 2004).
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The regulator of complement activation (RCA) gene cluster comprises genes for
FH, C4bp, DAF, CR1, CR2 and MCP. The RCA proteins consist of four to 60
short consensus repeats, eventually in addition to short transmembrane and
intracytoplasmic parts (CR1, CR2, MCP) or glycosylphosphatidylinositol (GPI)
anchors, as in the case of DAF (Nicholson et al. 1992). The SCR is a globular
domain of about 60 amino acids, with distinct conserved residues, e.g.
tryptophane, prolines, or, most importantly, four cysteines that form two disulfide
bonds (Cys1 to Cys3 and Cys2 to Cys4) (Prodinger et al. 1999).
The most important regulator of the CP is C1 inhibitor (C1-INH), which removes
active C1r and C1s from C1 complex thus preventing the assembly of C4b2b
(Tizard 2000). The next step in control occurs through cleavage of C4b by factor
I. Factor I is a plasma serine protease which is specific for C3b (and C4b). It
inactivates C3b (and C4b) by cleaving it into iC3b (and iC4b). Factor I requires a
cofactor, either C4bp (in fluid phase) or CR1 or MCP (in membranes). CR1
(CD35, C3b receptor) is present on erythrocytes and leucocytes. Proteins in the
RCA family negatively regulate C3 activation by disintegrating the convertases
(DAF) and serving as cofactors for factor I (Prodinger et al.1999).
Figure 1.9. The structure of the SCR and of SCR-based
complement regulators (Prodinger 1999)
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Proteins controlling the alternative pathway are factor I (together with its
cofactors FH, CR1 and MCP) and DAF (Prodinger et al, 1999). DAF is expressed
on red blood cells. FH is the main control protein in plasma, but also contributes
to dissociation of C3bBb on those parts of the cell membrane that are not
accessible to DAF (Muller-Eberhard 1988).
Control of the C5b-9 complex is mediated by three glycoproteins called
vitronectin, clusterin and most importantly CD59 (protectin) (Tizard 2000). CD59
is found on nucleated cells and on erythrocytes, but also in serum, urine and
milk. S protein, heparin lipoproteins, antithrombin III are able to bind to nascent
C5b-7 and to prevent its membrane insertion (Prodinger et al. 1999).
1.2.5  DISORDERS OF COMPLEMENT SYSTEM
An inherited deficiency of C3 is severe. C2 deficiency is sometimes found in
systemic lupus erythematosus (SLE) patients. Deficiency of C1-INH causes
hereditary angioedema (HAE). Paroxysmal noctural hemoglobinuria (PNH) is a
rare disease, in which a subset of blood cells lack GPI (glycophosphoinositol)-
anchored molecules such as CD59 and DAF.
1.2.6  COMPLEMENT EVASION STRATEGIES
Nonself structures are attacked first by AP and the lectin pathway and secondly
by the CP. Several microbes are known to have evolved mechanisms to resist
C3b deposition, opsonophagocytosis and lysis. Resistance mechanisms include
interference with C activation via poorly activating molecules on the surface of
the pathogens and trypsin/sialidase sensitive molecules (e.g. Trypanosoma
cruzi). Some microbes, such as Taenia solium paramyosin inhibit C1q/C1s
binding. Adsorption and incorporation of C regulatory proteins has been
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demonstrated by group A streptococci which bind FH via their M-proteins.
Proteolytic cleavage of C components such as C3 by Entamoeba histolytica
cystin protease and Leishmania major acid protease are interesting additional
mechanisms. Another mechanism is the use of C proteins provided by the host.
When HIV-1 is leaving an infected cell, it is coated by host cell membrane DAF
and CD59 molecules.
Several strategies can be in use at the same time. For example, the trematode
Schistosoma mansoni can modify its surface sialic acids, acquire DAF, bind and
cleave C4 and C3, cleave C9 to prevent MAC assemby and encode a protein
mimicking CD59.
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1.3  MALARIA IMMUNOLOGY
The mechanisms of immunity to malaria parasites are still not clearly understood.
The parasite is able to evade the immune response partially because the stage-
specific antigens vary from strain to strain. Typically these large proteins consists
of a series of long conserved regions, built up of repeated amino acid sequences,
interspersed with shorter variable regions  (such as var genes encoding PfEMP1)
which differ from strain to strain (Whittle 1994).
1.3.1  IMMUNITY TO MALARIA
1.3.1.1 GENETIC FACTORS
Natural, genetically determined partial immunity to malaria occurs in some
populations in malaria areas such as in West Africa, where there is a high
frequency of the sickle cell gene. This hemoglobin variant alters the
polymerisation of hemoglobin inhibiting invasion and growth of the plasmodia
within the red cells (Whittle 1994). Thus individuals heterozygous for the gene
are protected from severe malaria. Number of other genetic traits that affect the
red cell, such as the hemoglobin C and E genes, the glucose-6-phosphate
dehydrogenase deficiency gene and ?- and ?-thalassemia genes, decrease the
susceptibility to malaria infection. Also certain Duffy blood group antigens (Fy)
that are necessary for invasion of red cells in P. vivax infection and are rare in
Africans and certain HLA antigens may confer resistance to severe malaria
(Whittle 1994). Deposition of IgG and C3b fragments is shown to be remarkably
higher in ring-parasitized mutant erythrocytes resulting in enhanced phagocytosis
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by macrophages. This mechanism may explain protection against falciparum
malaria in sickle and beta-thalassemia trait (Ayj et al. 2004).
1.3.1.2  PASSIVE AND ACQUIRED IMMUNITY
IgG acquired transplacentally from the mother protects the infant against clinical
disease during the first 6 months of life thus demonstrating that antibodies alone
are suffficient to confer immunity to malaria. Immunoglobulin derived from Pf
immune adults could cure children with parasitemia (Whittle 1994).
Individuals surviving through early childhood develop partial clinical immunity
(Rogers 2003). In endemic areas Pf morbidity and mortality falls between 1 and 4
years. Pregnancy diminishes immunity to Pf. Without treatment, falciparum
infection ordinarily will terminate spontaneously in less than 1 year unless it ends
fatally (Brooks et al. 2001). An acquired strain-specific immunity has been
observed that appears to depend upon the presence of a low-level parasitemia
that somehow inhibits new infections or maintains the infection at a
nonsymptomatic level. This so called premunition or concomitant immunity is
soon lost after the parasites disappear from the blood. Exoerythrocytic forms in
the liver cannot support premunition alone and they elicit no inflammatory
response (Brooks et al. 2001).
High titres of antibody to the blood stage antigens such as the red cell surface
antigen, the merozoite surface antigen and soluble S antigens develop.
Cytokines produced by helper T cells, notably ?-interferon and TNF-? play a
central role in inhibiting parasite growth (Whittle 1994).
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1.3.2 COMPLEMENT IN MALARIA
Complement is activated in Plasmodium falciparum infection, even before
malaria can be detected microscopically. RBC-infected with Pf are protected from
C-mediated lysis by surface membrane glycosyl-phosphatidylinositol (GPI) –
anchored proteins, which include DAF and, especially, CD59. In malaria, C
activation causes destruction of infected and uninfected RBCs in a process
modulated by complement regulatory proteins (Pattanapanyasat et al. 2003).
Significant increase in C activation and MAC formation occured during blood
stage parasitemia despite the possible control of MAC formation by C regulatory
proteins on erythrocytes and the extremely low parasitemia (Roestenberg et al.
2007). Loss of red blood cell- C regulatory proteins (CR1 and DAF) and
increased level of circulating immune complexes are associated with severe
malarial anemia (Owuor 2008). Additional studies suggest that the levels of
expression of CR1 and DAF vary with age, being low in young children and
increasing with age, which might contribute to the severity of the disease (Stoute
2005).
Erythrocyte-bound opsonins known to induce erythrophagocytosis, i.e.
complement C3 fragments and autologous IgG, were increased in Pf patients
(Ekvall et al. 2001). In glucose-6-phosphate dehydrogenase (G6PD) deficiency
the amounts of membrane-bound C3 fragments were remarkably higher in rings
developing in red blood cells (RBCs). Phagocytosis of ring-parasitized mutant
RBCs was predominantly C-mediated. Enhanced phagocytosis of ring-
parasitized mutant RBCs may represent a common mechanism for malaria
protection in nonimmune individuals with G6PD-difiency (Ayi et al. 2004). In
patients with major haemolysis C deposition on RBCs correlated with haemolysis
over time. A similar mechanism for predominantly extravascular erythrocyte
clearance may be operative in acute malarial phase (Ekvall et al. 2001). Hematin
has been demonstrated to promote C AP-mediated deposition of C3 activation
fragments on RBCs (Pawluczkowycz et al. 2007). Hence, C activation may
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contribute to erythrophagocytosis and haemolysis in malaria.  On the other hand,
this has been associated with Pf complications, for example severe anemia
(Helegbe 2007).
Transmission of malaria is dependent upon the successful completion of the
sexual phase of the life cycle within the mosquito vector. Interrupting the
development of the sexual stages by preventing fertilization or the establishment
of zygotes on the mosquito midgut is recognized as a potential strategy for
control of malaria transmission. Complement mediated lysis of Pf gametes by
malaria-immune human sera is associated with antibodies to the Six-Cys Domain
Superfamily gamete surface antigen Pfs230. Recombinant Pfs230 induces
antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes.
These data suggest that Pfs230 is a major target of C-fixing antibodies which
may be important for antibody-mediated transmission-blocking immunity (Healer
et al. 1997). Pfs230 is processed from a precursor molecule Pfs260, which is
specifically cleaved, with membrane-associated Pfs230 fragment remaining on
the gamete surface, where it exists as a complex with Pfs48/45.
All Pfs230-specific transmission-blocking monoclonal antibodies (mAbs) studied
to date are directed against conformational epitopes and do not recognize the
protein in reduced form. Another common feature is that they are all of
complement-fixing immunoglobulin G subclasses and do not block parasite
development unless complement is present. Immunization of mice with part of
Pfs230 induced antibodies, which block transmission in the presence of C
(Healer et al. 1997). Furthermore, C3-like protein TEP1 has been demonstrated
to act as the determinant of vector capacity in the malaria vector Anopheles
gambiae. This C3-like protein has a role in phagocytosis, as revealed by an
dsRNA Anopheles gambiae knockout cell culture model (Blandin et al. 2004).
Structures similar to those found in C proteins C6, C7, C8, C9 and properdin can
also be found in plasmodial proteins. Thrombospondin-like repeats (TSRs) are
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present in the Pf sporozoite protein TRAP (thrombospondin related anonymous
protein) and in the circumsporozoite protein (CSP), a major surface protein on
the sporozoite. CR1 has been proposed to be the receptor for TSRs. CR1
polymorphism affects rosetting that confers protection against severe cerebral
malaria (Prodinger et al. 1999). PfEMP1 also mediates binding to CR1.
An apical sushi protein (ASP, PFD0295c) with the consencus SCR domain near
the C-terminus has been found with a predicted signal sequence and
transmembrane domain. This protein is located in apical organelles and
undergoes proteolytic processing and has also been proposed to have a role in
erythrocyte invasion. Orthologous genes have also been identified in the
genomes of several other plasmodium species (O’Keeffe et al. 2005).
Recent studies have demonstrated binding of the C3d region of C3b to the CSP
carboxy-terminus of murine P. berghei. The binding of C3d CR2-binding motif
has been suggested to mask epitopes on CSP and, thus, be a novel immune
escape mechanism of Pf sporozoites (Bergmann-Leitner et al. 2005).
The aim of the present study was to initiate studies on complement evasion
mechanisms of P. falciparum. For this, the binding of C3 and of the main C
inhibitors factor H and C4bp to parasitized RBCs and distinct recombinant
malarial parasites were analyzed.
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2  MATERIALS AND METHODS
2.1  FLOW CYTOMETRIC ANALYSIS
Parasitized and non-infected control RBCs obtained from Helsinki City Central
Hospital (with the patients’ informed consent) and from healthy laboratory
personnel, respectively, were washed with phosphate buffer saline (PBS) and
resuspended in PBS. 10 µl of cell suspension was added in 500 ?l of 1% BSA
(bovine serum albumin) / PBS and the cells were washed by centrifugation at
1000 x g for 4 min, 415 ?l of supernatant was removed and the pellet was
resuspended in 10 ?l of 10% HIS (heat inactivated normal human serum). NHS
was obtained from healthy laboratory personnel and inactivated by incubation at
56?C for 30 min. Samples were incubated at +4°C for 30 min. After washing (3x)
with 1% BSA/PBS as described, the primary antibody (2 µl of goat anti-FH, rabbit
anti-C3d (DAKO), 1:50 or 1 µl of monoclonal mouse anti-C4bp; 1:100) was
added and incubated at +4°C for 1 hour in the dark. Cells were washed for 3
times and the secondary antibody (2 µl of Alexa Fluor rabbit-anti-goat for FH,
Alexa Fluor goat-anti-rabbit for C3d and goat-anti-mouse for C4bp; 1:50) was
added and incubated at room temperature (RT) for 30 min in the dark. The cells
were washed with 1 % BSA/PBS twice and resuspended in 500 µl of 1%
BSA/PBS. The cells were analyzed on the flow cytometer (Becton Dickinson,
San Jose, CA) on the same day. A total of 50, 000 RBCs were analyzed for each
sample.
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2.2  ELISA
An antibody-detecting enzyme-linked immunosorbent assay (ELISA) was
designed to assess the binding of soluble complement inhibitors, FH and C4bp,
to Pf gametocyte/gamete membrane proteins Pfs230 (domains A-F) and Pfs
48/45 and sporozoite protein TRAP-TSR (obtained from Prof. Heikki Rauvala,
University of Helsinki), which have been associated with complement function in
previous studies. For the ELISA, Polysorp F96-plates (Nunc 082051) were
coated with Pf-samples (2 ?g/ml) in coating buffer (15 mM Na2CO3 and 35 mM
NaHCO3 pH  9,6,  60 ?l / well) and the plates were incubated at 4?C o/n. The
plates were washed with 400 ?l of 0.02 % Tween / VBS (veronal buffered saline)
for  5  times  and  blocked  with  1%  BSA  /  PBS,  400 ?l  /  well  at  RT  for  1  h.
Subsequently, the plates were rinsed once with Tween 0.02% / VBS and 100 ?l
of 0.5% HIS / PBS was added to the wells. After incubation at 37?C for 1 h the
plates were washed for 5 times as described above. The primary antibodies goat
anti-FH and sheep anti-C4bp (The Binding Site) diluted 1:10 000 in PBS, were
added and the plates were incubated at RT for 1 h and washed for 5 times. The
plates were incubated with horseradish peroxidase (HRP) -conjugated affinity-
purified secondary antibodies (Jackson Immunoresearch), rabbit-anti-sheep for
C4bp and donkey-anti-goat diluted 1:10 000 in PBS at RT for 1 h, and washed.
100 ?l of substrate solution (8 mg 1,2-phenylene-diamine hypochloride (OPD) +
12 ml dH2O + 5 ?l 30% H2O2) was added to each well. The reaction was stopped
by adding 100 ?l  of  2  M H2SO4 after color development and absorbances were
measured at 492 nm. Borrelia protein OspE obtained from Dr Ilkka Seppälä,
Haartman Institute, served as a positive control.
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2.3  SDS-PAGE GEL ELECTROPHORESIS
Two preparations (SDS soluble fraction, soluble parasite extract) of Pf merozoite
clones 3D7 and GB337 obtained from Ayman Khattab, Bernard Nocht Institute,
Hamburg, now at  the Haartman Institute, were lysed (50µl of each sample) by
sonication for 30 min. Protease inhibitor (Complement) was added 1:25 (2µl)
after sonication and the samples were run into an SDS-PAGE gel (10%).
2.4  IMMUNOBLOTTING ANALYSIS OF FACTOR H AND C4BP, C3, C4 AND
C9 BINDING
After SDS-PAGE the proteins were transferred onto a nitrocellulose membrane
for one hour using 50 mA / gel. The membrane was blocked with 5 % non-fat dry
milk in PBS o/n at +4°C. The membrane was incubated with 10% HIS for 1 h at
+37°C and washed 3 x with 0.05 % Tween / PBS and 3 x with PBS for 10 min
each. Primary antibody incubation was with polyclonal sheep anti-C4bp,
polyclonal goat anti-factor H, dilutions 1:5000 in 5 % non-fat dry milk / PBS,
polyclonal rabbit anti- C3c and -C4c or goat anti-C9 diluted 1:4000 in 5 % non-fat
dry milk / PBS overnight at +4°C. Washes were repeated as described above.
Secondary antibody incubation was with HRP-conjugated rabbit anti-sheep,
donkey anti-goat and goat anti-rabbit (Jackson ImmunoResearch), respectively,
1:5000 in 5% non fat dry milk / PBS for 1 h at +37°C. The membrane was
washed and the positive reactions were visualized by the
electrochemiluminescence method (ECL). The positive antibody controls were
goat anti-human C3, rabbit anti-C4c and goat anti-C9 (dilutions 1:200).
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2.5  AFFINITY CHROMATOGRAPHY
C3 was coupled to CNBr-activated Sepharose 4B particles (Amersham
Laboratories). 250 mg of the freeze-dried CNBr-activated sepharose 4B powder
was weighed out and 4.2 mg of C3 was used for coupling according to the
manufacturer’s instructions. 50 µl of Pf samples (3D7 soluble parasite extract)
were loaded and mixed on a rotatory shaker for 2 h at RT. The beads were
washed twice with 1 ml PBS and bound proteins were eluted with 100 µl of 0,1 M
glycine-HCl, pH 2. The eluent was subsequently neutralized with 1 M Tris-HCl pH
9.5. The samples were run into an SDS-PAGE gel (7.5 - 12.5 %) under
nonreducing conditions and eluted proteins were visualized by silver staining.
2.6  MATRIX ASSISTED LASER DESORPTION / IONISATION (MALDI)
To identify affinity chromatography isolated proteins MALDI mass spectrometry
was used. Protein containing samples were dried down from over 50 µl to 7-8  µl,
8 µl of Laemmli buffer was added, the samples were heated and run onto an 8%
SDS-PAGE gel. The gel was stained with Coomassie and with silver staining,
both staining for the same gel. Samples were further analysed with matrix
assisted laser desorption / ionisation (MALDI) at the Protein Chemistry Unit in
Biomedicum Helsinki.
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3  RESULTS
3.1  FACS ANALYSIS OF COMPLEMENT COMPONENT BINDING
In order to determine whether Pf evades C by acquisition of C inhibitors, we
tested the possibility that parasitized cells could bind soluble C inhibitors (FH,
C4bp) or C3 from the surrounding media. We studied the binding of C3, FH and
C4bp to parasitized and non-infected control cells by FACS after incubating cells
with HIS. Flow cytometry showed similar mean fluorescence intensity (MFI)
values for C4bp and C3 (analyzed by a C3d antibody) on the surfaces of RBCs in
patients and controls. Thus, no difference in binding of C4bp or C3d was
observed.
However, based on our results, there appeared to be an increased binding of FH
to parasitized cells compared to the control (average median fluorescence
intensity being 20,7 for parasitized samples and 5,3 for controls in three
experiments). Representative dot plots of RBC binding of FH in parasitized and
control samples are shown in figure 3.1 and histograms in figure 3.2.
Figure 3.1  A representative dot plot of FH-binding to P. falciparum –infected (on the left) and non-infected RBC’s sample
with anti-FH staining .
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Figure 3.2 Fluorescence histograms of FH-staining of P. falciparum-infected (on the left) and control samples.
3.2  ELISA ANALYSIS OF FH AND C4BP BINDING
We selected to study proteins that had previously been suggested to be
associated with C function. We did binding assays with FH and C4bp using
ELISA. No binding of FH or C4bp was detected to recombinant gametocyte
surface  proteins Pfs230, Pf48/45 nor to sporozoite protein TRAP-TSR (data not
shown).
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3.3  IMMUNOBLOTTING ANALYSES
The binding of FH, C4bp, C3c and C9 to whole parasites was analyzed by
immunoblotting. Two different preparations (SDS soluble fraction and soluble
parasite extraction) of two strains of Pf, namely 3D7 and GB337, were run on an
SDS-PAGE gel and transferred to a nitrocellulose membrane. Immunoblotting
with the polyclonal anti-factor C3c revealed attachment of C3 to the Pf proteins
(figure 3.4). The binding observed was shown not to be due to CR1 by
immunoblotting assays. No binding of factor H, C4bp or C9 on either of the two
Pf strains was observed.
Figure 3.4 Immunoblotting analysis of C3c-binding of Pf
3D7 and GB337 -samples. A potential C3c-binding protein
of ?200 kDa in soluble parasite extraction samples and
another band of ?70 kDa in 3D7 samples could be
observed. From left: molecular weight marker, GB337 SDS
soluble fraction 1:10 10 µl (lane 1), GB337 soluble parasite
extraction 1:10 10 µl (lane 2), 3D7 SDS soluble fraction
1:10 10 µl (lane 3), 3D7 soluble parasite extraction 1:10 10
µl (lane 4). Lanes 5 and 6 are the positive controls (goat
anti-C3 1:200 10 µl and HIS 1:500 10 µl, respectively)
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3.4  AFFINITY CHROMATOGRAPHY
We used an affinity chromatography column in order to identify and isolate the
potential C3 binding protein. After eluting, the suspension obtained was run on
an SDS-PAGE gel and molecular masses were determined after silver staining.
A faint band indicating a protein with a molecular mass of approximately 200 kDa
appeared on a gel. No Pf-protein, however, could be identified in further studies
(trypsin digestion + MALDI identification).
Figure 3.5 A  potential band of ?200 kDa (arrow) is visualised in elute after silver staining (lane 3). Lanes 1 and 2
represent original 3D7 soluble parasite extraction-sample and flow-through, respectively. Molecular weight marker on the
right (std).
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4 DISCUSSION
The purpose of this study was to examine the C evasion mechanisms of Pf. The
focus was on factors that regulate the activities of complement C3 convertases
on the surface of Pf. C3 convertases are central elements in C activation (Jarva
2004), which is known to occur in Pf infection.
In this study, a putative binding of FH to Pf-paratized erythrocytes was detected
by flow cytometry assays. With FACS, one of the problems was a low
parasitemia (< 2%), which we could not overcome by using Percoll gradient and
propidium iodide – fluorescein isothiocyanate (FITC) double staining (data not
shown). Parasite concentration methods, such as separating FACS or
immunomagnetic separation (Ribaut 2008), could facilitate molecular,
biochemical and immunological research of Pf. We also had quite few replicates
for FACS assays (3 in total). Furthermore, the elevation of FH-intensity was
general and parasitized erythrocytes were not clearly identified as a separe
group from uninfected patient RBCs. This may indicate that Pf infection causes
general changes that probably result from C activation.
On erythrocyte surface membranes, there are membrane-bound C inhibitory
proteins, especially CD59 and DAF (Pattanapanyasat et al. 2003), which protect
both normal and the RBC infected by Pf from C-mediated lysis. The level of
expression of CR1 and DAF is suggested to vary with age, being low in young
children and increasing with age, which might contribute to the severity of the
disease (Stoute 2005). Thus, it seems likely, that these membrane-bound C
inhibitors are more important in C evasion than soluble C inhibitors bound to Pf
antigens on infected RBCs.
In ELISA, no binding of soluble C inhibitors to gametocyte (Pfs230, Pfs 48/45) or
to sporozoite (TRAP-TSR) surface antigens was observed. Nevertheless,  it  is
possible that these proteins could have a role in protein-protein interactions (e. g.
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in attachment of Pf to host cells), as has been suggested for the apical sushi
protein (O’Keeffe et al. 2005). With regards to complement evasion, sporozoites
and sporozoite stage antigens would be of most interest, as this is the stage
where innate immunity plays an important role. A TSR-sequence has been
observed also in the major sporozoite surface protein, CSP (Prodinger et al.
1999). The binding of C3b to CSP carboxy-terminus in P. berghei that deviates
immune resistance (Bergmann-Leitner et al. 2005, 2007) makes the CSP protein
even more interesting (is this also detectable for Pf etc.).  Further studies are
thus needed to identify C3 binding on Pf.
In immunoblotting assays, there appered a potential C3-binding Pf protein.
However, in MALDI detection, no Pf protein could be observed. It has been
suggested that Plasmodium spp. merozoites adsorb C3 fragments on their
surface to gain entry into erythrocytes via CR1-receptor (Prodinger et al. 1999).
No acquisition of complement soluble inhibitors (FH or C4bp) was observed in
ligand blotting with merozoite-stage antigen.
In general, protozoan parasites and bacteria seem to use different kinds of
mechanisms of complement evasion. While bacteria mostly seem to bind host
complement regulators, protozoa often use endogenous factors for C3b
cleavage. It is possible that Pf interferes with C activation via other mechanisms,
e.g. via poorly activating molecules, such as polyanions, on the surface of the
pathogen.
In conclusion, in this study the mechanisms whereby Pf, an important malaria
pathogen, evades C3 convertase activity and C attack have been analyzed. Pf is
responsible for significant morbidity and mortality worldwide. A putative binding of
FH and C3 to Pf was observed, but further studies are needed. C evasion
mechanisms affect directly the virulence of the microbe. Thus, by identifying
factors whereby a particular microbe evades C, it is possible to understand better
how the microbe causes disease and, ultimately, how this could be prevented.
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